Traws Pharma (FRA:0T2) Current Accrued Expense : €2.18 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Current Accrued Expense?

Traws Pharma's Current Accrued Expense for the quarter that ended in Dec. 2023 was €2.18 Mil.

Traws Pharma's quarterly Current Accrued Expense declined from Jun. 2023 (€2.42 Mil) to Sep. 2023 (€2.29 Mil) and declined from Sep. 2023 (€2.29 Mil) to Dec. 2023 (€2.18 Mil).

Traws Pharma's annual Current Accrued Expense increased from Dec. 2021 (€1.70 Mil) to Dec. 2022 (€2.62 Mil) but then declined from Dec. 2022 (€2.62 Mil) to Dec. 2023 (€2.18 Mil).

Traws Pharma Current Accrued Expense Historical Data

The historical data trend for Traws Pharma's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Current Accrued Expense Chart

Traws Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

2.03

2.24

1.70

2.62

2.18

Traws Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial															2.62	3.18	2.42	2.29	2.18

Traws Pharma Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Traws Pharma Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Traws Pharma (FRA:0T2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (FRA:0T2) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

ONTX:USA

Address

12 Penns Trail, Newtown, PA, USA, 18940

Website

https://www.onconova.com

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Traws Pharma (FRA:0T2) Headlines

No Headlines